Clinical trials: Exudative Age Related Macular Degeneration
Exudative Age-related Macular Degeneration
Blood-aqueous Barrier Integrity in Eyes Undergoing Intravitreal Bevacizumab Therapy to Treat Neovascular AMD
The aim of this study is to evaluate the effect of repeated intravitreal bevacizumab injections on blood-aqueous barrier permeability in eyes with neovascular age-related macular degeneration (AMD).
- Trial name
- NCT03744806
- Testing
- Bevacizumab Injection
- Volunteers
- 48 people
- Sponsor
- Medical University of Lublin
Exudative Age-related Macular Degeneration
ProspectiveTrial of Proton Beam Combined With Anti-VEGF Therapy for Exudative Age-related Macular Degeneration (AMD)
The purpose of this study is to test the hypothesis that proton beam irradiation combined with intravitreal anti-VEGF therapy is safe and potentially more effective than intravitreal anti-VEGF therapy alone in eyes with exudative…
- Trial name
- PBAMD2 (NCT01213082)
- Testing
- 24GyE proton and Anti-VEGF, 16GyE and anti-VEGF
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of California, Davis
Exudative Age-Related Macular Degeneration
LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration
The purpose of this study is to evaluate the efficacy of 84 successive days of topically administered LHA510 compared to vehicle in reducing the number of patients requiring intravitreal (IVT) anti-vascular endothelial growth…
- Trial name
- NCT02355028
- Testing
- LHA510 ophthalmic suspension, LHA510 vehicle, Ranibizumab ophthalmic solution
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Alcon, a Novartis Company
Non-exudative Age-related Macular Degeneration
Non-exudative Age-related Macular Degeneration
Age-related macular degeneration (AMD) is the most prevalent cause of vision loss in developed countries and is often discussed in terms of the "dry" and the "wet" forms.
- Trial name
- NEAMD (NCT01712841)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Oregon Health and Science University
Exudative Age Related Macular Degeneration
Sirolimus in Conjunction With Eylea vs Eylea Alone for Exudative AMD
To determine safety and efficacy of intravitreal injections of Sirolimus with adjunct EYLEA in subjects with exudative age related macular degeneration (AMD) with persistent intraretinal or subretinal edema due to neovascular AMD…
- Trial name
- NCT02732899
- Testing
- Sirolimus, EYLEA
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Maturi, Raj K., M.D., P.C.
Exudative Age Related Macular Degeneration
Omega-3 Supplementation and Vitreal VEGF Levels in Wet-AMD
The purpose of this trial is to detect the influence of omega-3 supplements on vitreous levels of vascular endothelial growth factor (VEGF) in exudative age-related macular degeneration (AMD) in patients receiving intravitreal…
- Trial name
- NCT01819415
- Testing
- Anti-VEGF plus AREDS-2, Anti-VEGF plus AREDS-1
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Maisonneuve-Rosemont Hospital
Non-exudative (Dry) Age-related Macular Degeneration (AMD)
HELP Therapy for Dry AMD
This is an open-label, single center clinical investigation to evaluate the efficacy and safety of Heparin-induced Extracorporeal Lipoprotein Precipitation (H.E.L.P.) Therapy as a treatment for non-exudative (dry) Age-related…
- Trial name
- HELPuc (NCT01840683)
- Testing
- H.E.L.P. therapy (H.E.L.P. Plasmat Futura System)
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- B.Braun Avitum AG
Exudative Age-related Macular Degeneration
Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD
The purpose of the study is to determine the safety and efficacy of 4 monthly injections of iSONEP given alone or in combination with Lucentis, Avastin or Eylea in subjects with wet Age-related Macular Degeneration (AMD).
- Trial name
- Nexus (NCT01414153)
- Testing
- 4.0 mg iSONEP, 0.5 mg iSONEP, 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea
- Where
- 44 sites in United States
- Volunteers
- 158 people
- Sponsor
- Lpath, Inc.
Exudative Age-related Macular Degeneration
Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab
Exudative age-related macular degeneration (ARMD) is complicated by choroidal neovascularization (CNV). Although anti-vascular endothelial growth factor treatment is the gold standard treatment, recurrence is the main limitation…
- Trial name
- NCT01810042
- Testing
- ranibizumab
- Where
- 2 sites in South Korea
- Volunteers
- 49 people
- Sponsor
- Pusan National University Hospital
Exudative Age-related Macular Degeneration, Polypoidal Choroidal Vasculopathy
Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy
Effects of VEGF Trap-Eye (aflibercept) in treatment-naive polypoidal choroidal vasculopathy (PCV) will be evaluated.
- Trial name
- VAULT (NCT01950741)
- Testing
- aflibercept
- Where
- 8 sites in South Korea
- Volunteers
- 48 people
- Sponsor
- Pusan National University Hospital
Exudative Age-Related Macular Degeneration
Addition of 20mg/Day Zeaxanthin to Triple Therapy Treatment Options for Age Related Macular Degeneration (ARMD)
The purpose of this study is to evaluate the fact that 20 milligrams per day of oral Zeaxanthin as a supplement to patients with Choroidal neovascularization (CNV) and exudative age related macular degeneration (ARMD) undergoing…
- Trial name
- ARMD (NCT01527435)
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- The Retina Center of St. Louis County, PC
Exudative Age-Related Macular Degeneration
ESBA1008 Microvolume Study
The purpose of this study is to demonstrate a treatment effect of ESBA1008 applied as a microvolume injection or infusion on retinal function and morphology in subjects with exudative age-related macular degeneration (AMD).
- Trial name
- NCT01849692
- Testing
- ESBA1008 solution, Ranibizumab
- Volunteers
- 107 people
- Sponsor
- Alcon Research
Exudative Age-Related Macular Degeneration
Efficacy and Safety Study of ESBA1008 Versus EYLEA®
The purpose of this study is to compare the efficacy and safety of ESBA1008 versus EYLEA® in the treatment of exudative age-related macular degeneration.
- Trial name
- NCT01796964
- Testing
- ESBA1008 solution, Aflibercept
- Volunteers
- 173 people
- Sponsor
- Alcon Research
Exudative Age-related Macular Degeneration
Treat and Extend Therapy Study Using Intravitreal Aflibercept for Patients Exited From Protocol VGFT-OD 0910
The purpose of this research study is to determine if a "Treat and Extend" regimen (increasing the time between visits when the disease is stable and not getting worse) of aflibercept 2.0mg injections inside the eye for treating…
- Trial name
- RANGE (NCT01961414)
- Testing
- Aflibercept
- Where
- 6 sites in United States
- Volunteers
- 45 people
- Sponsor
- Palmetto Retina Center, LLC
Exudative Age-related Macular Degeneration
Macular Pigment Density Evolution in Unilateral Wet AMD Versus Non AMD Patients With or Without Lutein and Zeaxanthine Supplementation
•Purpose: Age-related Macular Degeneration ( AMD) is the leading cause of blindness and visual impairment in industrialized countries.
- Trial name
- NCT01404845
- Testing
- Nutrof Total, food supplement without Lutein and Zeaxanthin
- Where
- 2 sites in France
- Volunteers
- 200 people
- Sponsor
- Affordance
Exudative Age-related Macular Degeneration
FUSION Regimen: Combined Pro re Nata and Fixed Regimen Ranibizumab in Exudative Age-related Macular Degeneration
The purpose of this study is to investigate the safety and efficacy of a combined fixed-interval and a pro re nata (PRN) regimens of ranibizumab (FUSION regimen) for the treatment of exudative age-related macular degeneration…
- Trial name
- FUSION (NCT01500915)
- Testing
- Ranibizumab
- Where
- Spain
- Volunteers
- 17 people
- Sponsor
- Institut de la Macula y la Retina
Exudative Age-related Macular Degeneration
LUCAS (Lucentis Compared to Avastin Study)
Age-related macular degeneration (AMD) is the most common cause of blindness in individuals over 50 years of age. Bevacizumab and ranibizumab are two agents developed by the American pharmaceutical corporation Genentech, both of…
- Trial name
- LUCAS (NCT01127360)
- Testing
- Bevacizumab, Ranibizumab
- Where
- Norway
- Volunteers
- 420 people
- Sponsor
- Oslo University Hospital
Exudative Age-related Macular Degeneration
Evaluation of the Simplified Treat And Extend Regimen Using Ranibizumab in Exudative Age Related Macular Degeneration
Recently studies have shown that intravitreal injection of ranibizumab is effective for age related macular degeneration. However there are problems about injection regimen of maintenance phase.
- Trial name
- NCT02328209
- Testing
- ranibizumab
- Where
- Japan
- Volunteers
- 50 people
- Sponsor
- Mie University
Exudative Age-Related Macular Degeneration, Focal Vitreomacular Adhesion
Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion
This study will evaluate the safety and efficacy of Ocriplasmin intravitreal injection, in subjects diagnosed with exudative AMD with focal vitreomacular adhesion.
- Trial name
- MIVI-5 (NCT00913744)
- Testing
- Ocriplasmin
- Where
- 27 sites in United States, Belgium and 4 more
- Volunteers
- 100 people
- Sponsor
- ThromboGenics
Exudative Age-related Macular Degeneration
Study of Bimonthly VEGF Trap-Eye Compared to As-needed Administration or Other Therapy for Exudative Age-Related Macular Degeneration
Over the last several years, the standard of care for wet macular degeneration has become treatment with intravitreal injections of ranibizumab (Lucentis, Genentech), administered as frequently as every 4 weeks.
- Trial name
- NCT01526070
- Testing
- Intravitreal injection of Aflibercept
- Where
- United States
- Volunteers
- 142 people
- Sponsor
- Stanford University